Pandemic Response Lab (PRL), a wholly owned subsidiary of Opentrons Labworks, Inc., today announced two new three-target monkeypox tests, each developed and performed by its New York and Maryland laboratories, respectively. These skin lesion tests qualitatively detect three different viral genome targets of increasing specificity: non-variola orthopoxvirus, monkeypox virus species and monkeypox virus clade II. Use of these three viral targets identified by the Centers for Disease Control and Prevention (CDC) enhances the ability to detect mutant monkeypox virus strains.
The outbreak and spread of the monkeypox virus was declared a public health emergency by the World Health Organization and by the U.S. Department of Health and Human Services in August 2022, when more than 25,000 cases had been identified across all 50 states and Washington, D.C. These U.S. infections make up more than one-third of all cases globally. Currently, only a handful of commercial laboratories have authorization to offer one of the CDC tests that targets a single location in the virus genome common to all non-variola orthopoxvirus.
PRL
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!